Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 6, 1997, Pages 475-483

  Jones, Carleton B ^a   Clements, Mark K ^a   Wasi, Safia ^b   Daoud, Sayed S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Breast cancer; Camptothecin; Cell cycle; DNA topoisomerase I; Endothelial cells

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; LIPOSOME;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CATTLE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SENSITIVITY; ENCAPSULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; VEIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CATTLE; CELL CYCLE; CELL DIVISION; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM, VASCULAR; HUMANS; HYDROLYSIS; TUMOR CELLS, CULTURED;

EID: 0030844899     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050690     Document Type: Article

References (43)

1. Wall ME, Wani MC, Cook CE, Palmar KH, et al. (1966) Plant antitumor agents. The isolation and structure of camptothecin. a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888
2. Gottlieb JA, Guarino AM, Call JB, Oliverio TV, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camplothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461
3. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
4. Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515
5. Hertzberg RP, Caranfa MJ, Holden KG, Jakes DR, Gallagher G, et al. (1989) Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715
6. Burke T, Mi Z (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212(1): 285
7. Daoud SS, Fetouh MI, Giovanella BC (1993) Multilamelar liposomes as a delivery system for camptothecin and 9-amino-camptothecin. Proc Am Assoc Cancer Res 34: 2188
8. Daoud SS, Felouh MI, Giovanella BC (1995) Antitumor effects of liposome-incorporated camptothecin in human tumor xenografts. Anticancer Drugs 6: 83
9. Holm C, Covey JM, Kerrigan D, Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365
10. Hsiang YH, Lihou MG, Liu LF (1989) Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077
11. Pommier Y, Leteurtre F, Fesen M, Fujimori A, et al. (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530
12. Beidler DR, Chang J-Y, Zhou B-S, Cheng Y-C (1996) Camptothecin resistance involving steps subsequent to the formation of protein linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56: 345
13. Goldwasswer F, Shimizu T, Jackman J, Hoki Y, O'Conner PM, et al. (1996) Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430
14. Clements MK, Wasi S, Daoud SS (1996) Selective cytotoxicity of camptothecin (CPT) towards the human Clouser nut 1 breast carcinoma as compared to normal endothelial cells. Anticancer Drugs 7: 851
15. Jones CB, Clements MK, Wasi S, Daoud SS (1996) Sensitivity to camptothecin of human breast cancer cells and normal bovine endothelial cells, in vitro. Proc Am Assoc Cancer Res 37: 2956
16. Daoud SS, Forde HN (1991) Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells. Cancer Chemother Pharmacol 28: 370
17. Daoud SS, Juliano RL (1989) In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells. Cancer Chemother Pharmacol 23: 151
18. Tanizawa A, Bertrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y (1993) Cloning of Chinese hamster DNA topoisomerase 1 cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268: 25463
19. D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919
20. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271
21. Caron PR, Wang CJ (1993) DNA topoisomerases as targets of therapeutics: a structural overview. In: Andoh T, Ikeda H, Oguro M (eds) Molecular biology of DNA topoisomerases and its application to chemotherapy CRC Press, Boca Raton, pp 1-20
22. Tse-Dinh Y, Wang JC (1986) Complete nucleotide sequence of the topA gene encoding Escherichia coli DNA topoisomerase I. J Mol Biol 191: 321
23. Eng WS, Pandit D, Sternglanz R (1989) Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. J Biol Chem 264: 13373
24. Thrash C, Bankier AT, Barrell BG, Sternglanz R (1985) Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene. Proc Natl Acad Sci USA 82: 4374
25. D'Arpa P, Machlin PS, Ratric H, Rothfield NF, et al. (1988) cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxy-terminal fragment. Proc Natl Acad Sci USA 85: 2543
26. Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086
27. Giovanella BC, Steblin JS, Wall ME, Wani MC, et al. (1989) DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046
28. Zee AGJ van der, Hollenia H, Jong S de, Boonstra H, Gouw A, et al. (1991) P-glycoprotein expression and DNA topoisomer- ase I and II activity in benign tumor of the ovary and in malignant tumor of the ovary, before and after platinum cyclophosphamide chemotherapy. Cancer Res 51: 5915
29. Husain I, Mohler LJ, Seigler FH, Besterman MJ (1994) Elevation of topoisomerase I messenger RNA. protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539
30. Fox SB, Gatter CK, Bicknell R, Going JJ, et al. (1993) Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53: 4161
31. Benekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181
32. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1
33. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722
34. Beidler DR, Cheng YC (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47: 907
35. O'Conner PM, Nieves-Neira W, Kerrigan D, Bertrand R (1991) S-Phase population analysis does not correlate with the cytotoxicity of camptothecin and 10.11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun 3(8): 233
36. Perego P, Capranico G, Supino R, Zunino F (1994) Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5: 645
37. Bronstein IB, Vorobyev S, Timofeev A, Jolles JC, Alder LS, Holden AJ (1996) Elevation of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8(1): 17
38. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E (1995) The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9: 1013
39. Chow KC, Ross WE (1987) Topoisomerase-specitic drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7: 3119
40. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629
41. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC (1993) Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53: 1577
42. Pines J (1995) Cyclins, edks and cancer. Semin Cancer Biol 6: 63
43. ede2 cyclin B. Cancer Res 52: 1823